CLM3, a multitarget tyrosine kinase inhibitor with antiangiogenic properties, is active against primary anaplastic thyroid cancer in vitro and in vivo. (Q39034547)
Jump to navigation
Jump to search
scientific article published on January 2014
Language | Label | Description | Also known as |
---|---|---|---|
English | CLM3, a multitarget tyrosine kinase inhibitor with antiangiogenic properties, is active against primary anaplastic thyroid cancer in vitro and in vivo. |
scientific article published on January 2014 |
Statements
CLM3, a multitarget tyrosine kinase inhibitor with antiangiogenic properties, is active against primary anaplastic thyroid cancer in vitro and in vivo (English)
Simona Piaggi
Alessandro Antonelli
Guido Bocci
Silvia Martina Ferrari
Caterina Mancusi
Anna Fioravanti
Alessandro Corti
Gabriele Materazzi
Claudio Spinelli